iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: http://pubmed.ncbi.nlm.nih.gov/32342443/
Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun;10(3):515-521.
doi: 10.1007/s13555-020-00379-7. Epub 2020 Apr 27.

Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study

Elisa Molinelli  1 , Anna Campanati  2 , Valerio Brisigotti  2 , Claudia Sapigni  2 , Matteo Paolinelli  2 , Annamaria Offidani  2
Affiliations

Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study

Elisa Molinelli et al. Dermatol Ther (Heidelb). 2020 Jun.

Abstract

Introduction: Alopecia areata (AA) is a chronic inflammatory non-scarring type of hair loss. Current therapies for alopecia areata are rather limited and mainly involve the use of topical, intra-lesional or systemic steroids and topical immunotherapy, with variable benefit. Recent studies have demonstrated that vitamin D analogues could potentially promote hair growth in patients with patchy AA.

Methods: We investigated the efficacy and safety of treatment with calcipotriol, a synthetic derivative of vitamin D (calcipotriol 0.005% ointment), versus treatment with the corticosteroid clobetasol (topical clobetasol 0.05% formulation), in a series of 35 patients with scalp AA, using an intrasubject design.

Results: Patches treated with calcipotriol ointment showed greater and faster response rates than did those treated with topical clobetasol, although the differences were not statistically significant. The main strength of the study is its prospective design; the main limitation is the small number of participants.

Conclusions: Treatment with the calcipotriol would appear to be reasonably effective in patients with mild to moderate patchy AA and was associated with only limited and reversible side effects.

Keywords: Alopecia areata; Calcipotriol; Clobetasol; Therapy; Treatment; Vitamin D analogue.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78:1–12. doi: 10.1016/j.jaad.2017.04.1141. - DOI - PubMed
    1. Ganzetti G, Campanati A, Offidani A. Alopecia areata: a possible extraintestinal manifestation of Crohn’s disease. J Crohns Colitis. 2012;6:962–963. doi: 10.1016/j.crohns.2012.05.023. - DOI - PubMed
    1. Lee S, Lee WS. Management of alopecia areata: updates and algorithmic approach. J Dermatol. 2017;44:1199–1211. doi: 10.1111/1346-8138.13933. - DOI - PubMed
    1. Ganzetti G, Campanati A, Simonetti O, Cataldi I, Giuliodori K, Offidani A. Videocapillaroscopic pattern of alopecia areata before and after diphenylciclopropenone treatment. Int J Immunopathol Pharmacol. 2008;24:1087–1091. doi: 10.1177/039463201102400428. - DOI - PubMed
    1. Çerman AA, Solak SS, Altunay İ, Küçükünal NA. Topical calcipotriol therapy for mild-to-moderate alopecia areata: a retrospective study. J Drugs Dermatol. 2015;14:616–620. - PubMed

LinkOut - more resources